Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-25

FDA Approved: COTEMPLA XR-ODT — Supplemental Application (Neos Therapeutics Brands, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Cotempla XR-ODT (methylphenidate) by Neos Therapeutics Brands, LLC, for the treatment of attention-deficit/hyper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COTEMPLA XR-ODT (METHYLPHENIDATE)

Snippet

SUPPL AP for COTEMPLA XR-ODT (METHYLPHENIDATE)